Few decisions in metabolic medicine draw as many questions as semaglutide vs tirzepatide. Both are injectable incretin therapies, both reshaped obesity treatment, and both are frequently discussed interchangeably. They are not interchangeable. This is an evidence-based comparison of how they differ, what the trials actually measured, and how clinicians think about choosing between them.
The Core Difference: One Receptor vs Two
The cleanest way to understand these drugs is by their targets.
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, an incretin hormone that enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite through central signaling.
Tirzepatide is a dual GIP and GLP-1 receptor agonist. It engages the GLP-1 receptor like semaglutide, but also activates the glucose-dependent insulinotropic polypeptide (GIP) receptor. The prevailing hypothesis is that combined incretin activity produces additive metabolic effects, though the exact contribution of GIP is still an active research question.
That single structural distinction — one pathway versus two — is the thread running through every efficacy difference below.
Head-to-Head: The SURPASS-2 Trial
Most drug comparisons rely on cross-trial guesswork. Semaglutide and tirzepatide are unusual because they were tested directly against each other.
SURPASS-2 randomized adults with type 2 diabetes to tirzepatide (5, 10, or 15 mg) or semaglutide 1 mg weekly. At 40 weeks:
- HbA1c reduction: tirzepatide lowered HbA1c by up to roughly 2.3 to 2.5 percent versus about 1.9 percent for semaglutide.
- Body weight: tirzepatide produced up to about 12 kg of weight loss at the 15 mg dose versus roughly 6 kg for semaglutide 1 mg.
Tirzepatide was statistically superior on both endpoints at every dose. This is the strongest single piece of comparative evidence available, and it consistently favors the dual agonist.
One caveat matters: the comparator was semaglutide 1 mg, the diabetes dose. The obesity formulation is titrated to 2.4 mg, which was not the arm tested here.
Obesity Trials: SURMOUNT vs STEP
For weight loss specifically, each drug has its own flagship program.
- STEP-1 (semaglutide 2.4 mg): mean weight loss of about 15 percent at 68 weeks.
- SURMOUNT-1 (tirzepatide): mean weight loss of up to about 20.9 percent at the highest dose at 72 weeks.
These are separate trials with different populations and timelines, so the comparison is indirect. But the direction agrees with SURPASS-2: tirzepatide’s ceiling appears higher.
For a deeper look at the underlying data, the research hub collects the landmark GLP-1 trials, and the weight loss condition page maps which compounds carry the strongest evidence.
Side Effects: A Shared Class Profile
Because both drugs act on GLP-1, their tolerability profiles rhyme. The dominant adverse events for each are gastrointestinal:
- Nausea
- Vomiting
- Diarrhea
- Constipation
These are typically most intense during dose escalation and fade as the body adapts. Both drugs are titrated slowly for exactly this reason. Serious adverse events were uncommon in trials, and discontinuation rates for GI effects were broadly comparable between the two.
Neither should be used by people with a personal or family history of medullary thyroid carcinoma or MEN 2, consistent with the class labeling.
How Clinicians Choose
The trial data lean toward tirzepatide on raw efficacy, but “more weight loss” is not the only variable in a real prescription. Access, insurance coverage, tolerability, comorbidities, and individual response all shape the decision. Some people tolerate one better than the other; some plateau on one and respond to a switch.
The honest summary: tirzepatide has demonstrated larger average effects in controlled trials, while semaglutide has the longer real-world track record and a robust cardiovascular outcomes dataset. Both are legitimate, evidence-backed options, and the right choice is individual.
The Bottom Line
On the specific question of semaglutide vs tirzepatide, the controlled evidence favors tirzepatide for magnitude of weight and glucose reduction, driven by its dual GIP/GLP-1 mechanism. Semaglutide remains a first-line, extensively studied option with strong outcomes data of its own. Neither is a shortcut, and both require medical supervision, dose titration, and realistic expectations.
Explore the full peptide encyclopedia to compare mechanisms, status, and evidence across the metabolic class — and always discuss options with a qualified provider before starting therapy.